Login to Your Account

China aiming to align with global naming rules for biologics, biosimilars

By Cornelia Zou
Staff Writer

Friday, May 20, 2016

BEIJING – China is working on an improved naming system for biologics and biosimilars to better ensure drug safety and good drug administration, according to national authorities. And the system would bring the country closer to internationally recognized naming rules.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription